On the label of the vaccine, there will be a warning about the risk of a rare side effect, and instructions will also be provided
After the use of the Johnson & Johnson COVID vaccine was temporarily suspended after reports of thrombosis, Europe decided to resume the distribution of the vaccine.
This is reported by Reuters.
The European regulator believes that the benefits of the American vaccine outweigh the risks.
As J&J Chief Scientist Paul Stoffels said, trust in the vaccine can be restored thanks to clear diagnostic and therapeutic recommendations.
In turn, the European Health Regulator and the European Medicines Agency (EMA) said that the benefits of a single injection outweigh the risks, recommending that the vaccine label warn of the risk of a rare side effect and provide instructions on how to recognize and treat it.
Earlier, the media reported that the European Commission in 2022 will not extend the contracts for the supply of vaccines to AstraZeneca and Johnson & Johnson.